Although the use of selective estrogen receptor modulators such as tamoxifen is able to prevent development of certain estrogen receptor (ER)-positive breast cancer, they have not been widely adopted as a long-term preventive strategy because of incomplete effectiveness and intolerable adverse effects [4]. This evidence concerns the gene ESR1 and breast cancer.